Patents by Inventor David Griffith

David Griffith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Framework selection
    Patent number: 9249232
    Abstract: The present invention relates to improved methods for the selection of appropriate human acceptor framework regions for non-human (donor) antibodies and methods for obtaining humanized antibodies of high affinity using such acceptor frameworks.
    Type: Grant
    Filed: June 26, 2007
    Date of Patent: February 2, 2016
    Assignee: UCB BioPharma SPRL
    Inventors: Ralph Adams, Alastair David Griffiths Lawson, Andrew George Popplewell, Kerry Louise Tyson
  • CAPSULE DISPENSING CONTAINER
    Publication number: 20150335586
    Abstract: A package for delivering a single-dose product includes a softgel capsule which is comprised of at least one gelling agent selected from protein-based gelling agents and polysaccharide-based gelling agents. The capsule shell includes one or more areas of reduced thickness that are preferentially ruptured by exertion of a compressive force on the softgel capsule to create an opening in the capsule shell through which the fill composition can be delivered by spraying or squeezing. A method for manufacturing the softgel capsule having one or more areas of reduced shell thickness is also described.
    Type: Application
    Filed: May 8, 2015
    Publication date: November 26, 2015
    Applicant: R.P. SCHERER TECHNOLOGIES, LLC
    Inventors: Laura Baruzzi, David Griffith Williams, SR., Arianna Provenza, Rodrigo Fuscelli Pytel
  • In vitro evolution in microfluidic systems
    Patent number: 9186643
    Abstract: The invention describes a method for isolating one or more genetic elements encoding a gene product having a desired activity, comprising the steps of: (a) compartmentalizing genetic elements into microcapsules; and (b) sorting the genetic elements which express the gene product having the desired activity; wherein at least one step is under microfluidic control. The invention enables the in vitro evolution of nucleic acids and proteins by repeated mutagenesis and iterative applications of the method of the invention.
    Type: Grant
    Filed: December 3, 2012
    Date of Patent: November 17, 2015
    Assignees: Medical Research Council, President and Fellows of Harvard College
    Inventors: Andrew David Griffiths, David A. Weitz, Darren R. Link, Keunho Ahn, Jerome Bibette
  • PRONE CART
    Publication number: 20150320624
    Abstract: A prone cart for transporting a patient in a hospital or clinic setting is provided. The prone cart includes a frame having a pair of extension slides coupled thereto and first and second sets of wheels. An upper portion includes first and second moveably adjustable trays operably coupled to said extension slides. The second tray includes a plurality of apertures in at least one side rail and the first tray includes at least one locking spring pin operably receivable by one of said plurality of apertures. The prone cart also includes a patient support surface.
    Type: Application
    Filed: January 23, 2015
    Publication date: November 12, 2015
    Inventors: Lynda Woodman, Gary J. Kroll, Karen Cepress, Amy Schulz, Kath Roske, Paula Braaten, David Griffith
  • N1/N2-lactam acetyl-CoA carboxylase inhibitors
    Patent number: 9181252
    Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein G is R1, R2 and R3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: November 10, 2015
    Assignee: Pfizer Inc.
    Inventors: David A. Griffith, Robert L. Dow, Scott W. Bagley, Aaron Smith
  • Hybrid force sensitive touch devices
    Patent number: 9170677
    Abstract: A hybrid touch-screen display that integrates force-based touch-screen technology with any one from among a group of projective capacitive, surface capacitive, resistive, digital resistive, SAW, IR, APR, DST, optical and electromagnetic touch-screen technologies to provide an ability to compensate for non-perfect force transfer. An alternate implementation is also disclosed that employs a single force sensor for relative force measurement in a system in which force is traditionally not measured, here a water dispenser unit. This allows compensation for varying static loads, run-time calibration, and filtering of extraneous loads through firmware.
    Type: Grant
    Filed: June 11, 2013
    Date of Patent: October 27, 2015
    Assignee: Apple Inc.
    Inventors: Anders L. Mölne, David Griffith
  • FUNCTION MODIFYING NAv1.7 ANTIBODIES
    Publication number: 20150232553
    Abstract: A Nav1.7 binding entity that after binding functionally modifies the activity of the ion channel, in particular an anti-Nav1.7 antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.
    Type: Application
    Filed: December 30, 2014
    Publication date: August 20, 2015
    Inventors: Helene Margaret Finney, Terence Seward Baker, Alastair David Griffiths Lawson, Karen Margrete Miller, Marc Roger de Ryck, Christian Gilbert J. Wolff
  • ANTIBODY MOLECULES WHICH BIND IL-17A AND IL-17F
    Publication number: 20150218271
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Application
    Filed: April 20, 2015
    Publication date: August 6, 2015
    Inventors: Ralph Adams, Terence Seward Baker, Alastair David Griffiths Lawson
  • Method for Identifying Compounds of Therapeutic Interest
    Publication number: 20150219635
    Abstract: The present invention relates to an improved method for drug discovery. In particular the present invention provides a method of identifying compounds capable of binding to a functional conformational state of a protein of interest or protein fragment thereof, said method comprising the steps of: (a) Binding a function-modifying antibody to the target protein of interest or a fragment thereof to provide an antibody-constrained protein or fragment, wherein the antibody has binding kinetics with the protein or fragment which are such that it has a low dissociation rate constant, (b) Providing a test compound which has a low molecular weight, (c) Evaluating whether the test compound of step b) binds the antibody constrained protein or fragment, and (d) Select a compound from step c) based on the ability to bind to the protein or fragment thereof.
    Type: Application
    Filed: June 28, 2013
    Publication date: August 6, 2015
    Inventors: Alastair David Griffiths Lawson, Alistair James Henry
  • ANTIBODIES TO ION CHANNELS
    Publication number: 20150203571
    Abstract: An anti-E1 ion channel antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.
    Type: Application
    Filed: November 19, 2014
    Publication date: July 23, 2015
    Inventors: Karen Margrete Miller, Marc Roger De Ryck, Christian Gilbert J. Wolff, Alastair David Griffiths Lawson, Helene Margaret Finney, Terence Seward Baker
  • High velocity fluid flow electric heater
    Patent number: 9074819
    Abstract: An electrical heater has first and second heater elements, each having a hairpin-shaped metal tube with an upstream and a downstream leg and tube ends adjacent each other. An electrical resistance wire surrounded by insulation powder extends through the tube. Electrical terminals join to the wire and protrude from each of the tube ends. Conduits enclose the upstream and the downstream legs of the heater elements, providing a continuous annular flow path. A manifold has heater element passages for end portion of the legs. An inlet passage in the manifold leads from an exterior portion of the manifold to the annular flow path surrounding the upstream leg of the first heater element. A transfer passage within the manifold leads from the annular flow path surrounding the downstream leg of the first heater element to the annular flow path surrounding the upstream leg of the second heater element.
    Type: Grant
    Filed: April 4, 2012
    Date of Patent: July 7, 2015
    Assignee: Gaumer Company, Inc.
    Inventors: Craig S. Tiras, David Griffith
  • N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS
    Publication number: 20150152109
    Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein G is R1, R2 and R3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
    Type: Application
    Filed: February 13, 2015
    Publication date: June 4, 2015
    Applicant: PFIZER INC.
    Inventors: David A. Griffith, Robert L. Dow, Scott W. Bagley, Aaron Smith
  • DNA encoding antibody molecules which bind IL-17A and IL-17F
    Patent number: 9034600
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: May 19, 2015
    Assignee: UCB Biopharma SPRL
    Inventors: Ralph Adams, Terence Seward Baker, Alastair David Griffiths Lawson
  • MICROFLUIDIC DEVICES FOR RELIABLE ON-CHIP INCUBATION OF DROPLETS IN DELAY LINES
    Publication number: 20150132837
    Abstract: The present invention relates generally to droplet creation, fusion and sorting, and incubation for droplet-based microfluidic assays. More particularly, the present invention relates to delay-lines, which allow incubation of reactions for precise time periods. More particularly, the present invention relates to delay lines for incubations up to three hours, while reducing back-pressure and dispersion in the incubation time due to the unequal speeds with which droplets pass through the delay line.
    Type: Application
    Filed: January 27, 2015
    Publication date: May 14, 2015
    Inventors: LUCAS FRENZ, KERSTIN GODELINDE BLANK, ANDREW DAVID GRIFFITHS, ERIC BROUZES
  • Vitro evolution in microfluidic systems
    Patent number: 9029083
    Abstract: The invention describes a method for isolating one or more genetic elements encoding a gene product having a desired activity, comprising the steps of: (a) compartmentalising genetic elements into microcapsules; and (b) sorting the genetic elements which express the gene product having the desired activity; wherein at least one step is under microfluidic control. The invention enables the in vitro evolution of nucleic acids and proteins by repeated mutagenesis and iterative applications of the method of the invention.
    Type: Grant
    Filed: October 10, 2005
    Date of Patent: May 12, 2015
    Assignees: Medical Research Council, President and Fellows of Harvard College
    Inventors: Andrew David Griffiths, David Weitz, Darren Link, Keunho Ahn, Jerome Bibette
  • Anti-FcRn Antibodies
    Publication number: 20150118240
    Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
    Type: Application
    Filed: May 13, 2013
    Publication date: April 30, 2015
    Inventors: Helene Margaret Finney, Alastair David Griffiths Lawson, Stevan Graham Shaw, Bryan John Smith, Kerry Louise Tyson, Lara Kevorkian, Christoph Meier, Kaushik Sarkar, Paul Alan Atherfold
  • N1/N2-lactam acetyl-CoA carboxylase inhibitors
    Patent number: 8993586
    Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein G is R1, R2 and R3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: March 31, 2015
    Assignee: Pfizer Inc.
    Inventors: David A. Griffith, Robert L. Dow, Scott W. Bagley, Aaron Smith
  • DNA encoding function modifying Na1.7 antibodies
    Patent number: 8986954
    Abstract: A Nav1.7 binding entity that after binding functionally modifies the activity of the ion channel, in particular an anti-Nav1.7 antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.
    Type: Grant
    Filed: May 23, 2014
    Date of Patent: March 24, 2015
    Assignee: UCB Pharma S.A.
    Inventors: Helene Margaret Finney, Terence Seward Baker, Alastair David Griffiths Lawson, Karen Margrete Miller, Marc Roger de Ryck, Christian Gilbert J. Wolff
  • production of ultrapure EPA and polar lipids form largely heterotrophic culture
    Publication number: 20150057353
    Abstract: Eicosapentaenoic acid (EPA) compositions and EPA-rich polar lipids for prophylactic or therapeutic applications are described. Production from certain cultured micro-organisms (like Nitzschia laevis) promotes synthesis of EPA, including polar lipids including EPA. The EPA-rich polar lipids themselves may be used as polar compounds. EPA can be selectively hydrolyzed from particular positions in isolated polar lipids by lipase activity, then optionally further purified. The process bypasses reliance on diminishing fish stocks and on physico-chemical processes that may not adequately separate desirable n-3 HUFAs from unwanted products like DHA also found in fish oil and cultured organisms.
    Type: Application
    Filed: November 3, 2014
    Publication date: February 26, 2015
    Inventors: Karl Thomas GEIRINGER, Hywel David Griffiths
  • N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS
    Publication number: 20150025098
    Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein G is R1, R2 and R3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
    Type: Application
    Filed: September 26, 2014
    Publication date: January 22, 2015
    Applicant: PFIZER INC.
    Inventors: David A. Griffith, Robert L. Dow, Scott W. Bagley, Aaron Smith